These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19223643)

  • 1. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
    Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
    Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.
    Zhou XJ; Garner RC; Nicholson S; Kissling CJ; Mayers D
    J Clin Pharmacol; 2009 Dec; 49(12):1408-16. PubMed ID: 19776293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.
    Zala C; St Clair M; Dudas K; Kim J; Lou Y; White S; Piscitelli S; Dumont E; Pietropaolo K; Zhou XJ; Mayers D
    Antimicrob Agents Chemother; 2012 May; 56(5):2570-5. PubMed ID: 22314532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
    Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
    Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
    Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers.
    Eiznhamer DA; Creagh T; Ruckle JL; Tolbert DT; Giltner J; Dutta B; Flavin MT; Jenta T; Xu ZQ
    HIV Clin Trials; 2002; 3(6):435-50. PubMed ID: 12501127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
    Dousson C; Alexandre FR; Amador A; Bonaric S; Bot S; Caillet C; Convard T; da Costa D; Lioure MP; Roland A; Rosinovsky E; Maldonado S; Parsy C; Trochet C; Storer R; Stewart A; Wang J; Mayes BA; Musiu C; Poddesu B; Vargiu L; Liuzzi M; Moussa A; Jakubik J; Hubbard L; Seifer M; Standring D
    J Med Chem; 2016 Mar; 59(5):1891-8. PubMed ID: 26804933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
    Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the pharmacokinetics of abacavir.
    Yuen GJ; Weller S; Pakes GE
    Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
    Schürmann D; Rudd DJ; Zhang S; De Lepeleire I; Robberechts M; Friedman E; Keicher C; Hüser A; Hofmann J; Grobler JA; Stoch SA; Iwamoto M; Matthews RP
    Lancet HIV; 2020 Mar; 7(3):e164-e172. PubMed ID: 31911147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
    Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects.
    Creagh T; Ruckle JL; Tolbert DT; Giltner J; Eiznhamer DA; Dutta B; Flavin MT; Xu ZQ
    Antimicrob Agents Chemother; 2001 May; 45(5):1379-86. PubMed ID: 11302799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
    Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
    Martin DE; Blum R; Doto J; Galbraith H; Ballow C
    Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    J Clin Pharmacol; 2001 Oct; 41(10):1098-105. PubMed ID: 11583478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.